|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
46.45 USD |
-0.92% | -8.15% | -17.87% | |
Published on 05/09/2025 at 20:21
This article is reserved for members Unlock the article: REGISTER NOW!
© Reuters – 2025
|
Hawaii in $700 million settlement with Bristol-Myers, Sanofi over Plavix warning label |
08:21pm |
RE |
|
US court shuts down AstraZeneca’s challenge to Medicare drug price plan |
May. 08 |
RE |
|
Trump to sign order on drug prices as early as next week, Politico reports |
May. 07 |
RE |
|
Trump to sign order on drug prices as early as next week, Politico reports |
May. 07 |
RE |
|
Bristol Myers Squibb Says Shareholder Proposal On Request To Cease DEI Efforts Not Approved At Annual Meeting – SEC Filing |
May. 07 |
RE |
|
Declaration of Voting Results by Bristol-Myers Squibb Company |
May. 07 |
CI |
|
Gilead boosts planned US investments by $11 billion amid tariff threat |
May. 07 |
RE |
|
Bristol Myers Squibb Announces Executive Changes |
May. 06 |
CI |
|
Powell’s Shadow Looms Over Nervous Markets |
May. 06 |
 |
|
Bristol Myers to invest $40 billion in the US over 5 years |
May. 05 |
RE |
|
Bristol Myers to invest $40 billion in the US over 5 years, CEO says |
May. 05 |
RE |
|
Piper Sandler Adjusts Bristol-Myers Squibb’s Price Target to $66 From $65 |
Apr. 30 |
MT |
|
Bristol-Myers’ New Injection Version of Opdivo Gets UK Approval |
Apr. 30 |
MT |
|
UK’s MHRA Authorises Cancer Treatment Variation With An Administration Time Of 3-5 Minutes |
Apr. 30 |
RE |
|
Analyst recommendations: Meta Platforms, Progressive, Equifax, SBA Communications, Cadence Design Systems… |
Apr. 29 |
|
|
Redburn Atlantic Adjusts Price Target on Bristol-Myers Squibb to $48 From $54, Maintains Neutral Rating |
Apr. 29 |
MT |
|
Alexandria Real Estate reduces annual FFO forecast on lower leasing demand |
Apr. 28 |
RE |
|
HSBC Adjusts Bristol-Myers Squibb Price Target to $47 From $56, Maintains Hold Rating |
Apr. 28 |
MT |
|
Goldman Sachs Adjusts Price Target on Bristol-Myers Squibb to $56 From $55, Maintains Neutral Rating |
Apr. 25 |
MT |
|
Wells Fargo Adjusts Price Target on Bristol-Myers Squibb to $53 From $62, Maintains Equalweight Rating |
Apr. 25 |
MT |
|
Report Says 25% Pharma Tariff Would Raise US Drug Costs by $51 Billion Annually |
Apr. 25 |
MT |
|
Report Says 25% Pharma Tariff Would Raise US Drug Prices by $51 Billion Annually, Reuters Reports |
Apr. 25 |
MT |
|
US pharma tariffs would raise US drug costs by $51 billion annually, report finds |
Apr. 25 |
RE |
|
JPMorgan Cuts Price Target on Bristol-Myers Squibb to $67 From $70 |
Apr. 24 |
MT |
|
WRAPUP 5-Trump trade war spreads more gloom across businesses worldwide |
Apr. 24 |
RE |
BMY: Dynamic Chart
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l’hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
More about the company
Buy
Average target price
57.20USD
Spread / Average Target
+23.15%
Consensus
Quarterly revenue – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
